Israel’s Bonus BioGroup reports a survival rate of 94 percent (47 of 50) of the severe COVID-19 patients treated with its drug product MesenCure in a Phase II, multicenter clinical trial.
The post New Miracle Drug Saves 94 Percent of Desperately Ill COVID Patients in Trial appeared first on The Washington Informer.